MarketCap
Retractable Technologies RVP
$ 0.68
0.03%
Facebook
X
Telegram
Retractable Technologies Operating Income | RVP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Retractable Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.2 M | -21.1 M | -11.5 M | -853 K | 72.6 M | 24.1 M | 2.97 M | -1.33 M | -3.78 M | -3.51 M | -3.21 M | -2.16 M | -5.93 M | -3.94 M | -4.09 M | -6.66 M | -13.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.6 M | -21.2 M | -170 K |
Quarterly Operating Income Retractable Technologies
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.17 M | -3.65 M | -5.13 M | -4.68 M | - | -5.14 M | -5.76 M | -2.99 M | - | -936 K | -5.03 M | -2.74 M | - | -691 K | -2.06 M | 9.73 M | - | 7.97 M | 12.7 M | 23.4 M | - | 10.3 M | 960 K | 481 K | - | 978 K | 329 K | -175 K | - | -60.2 K | -939 K | -157 K | - | -32.9 K | -1.31 M | -1.15 M | - | -81.4 K | -606 K | -894 K | - | -199 K | -1.24 M | -895 K | - | 421 K | -1.34 M | -1.99 M | - | -825 K | -2.39 M | -1.37 M | - | -211 K | -532 K | -645 K | - | -26.4 K | -988 K | -99.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.4 M | -6.17 M | 90.9 K |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Alcon
ALC
|
1.36 B | $ 67.76 | 0.03 % | $ 33.4 B |  Schweiz |
 |
AngioDynamics
ANGO
|
-39.9 M | $ 15.68 | 1.1 % | $ 651 M | USA |
 |
AtriCure
ATRC
|
-9.45 M | $ 56.22 | 0.77 % | $ 2.68 B | USA |
 |
Baxter International
BAX
|
-308 M | $ 23.71 | 0.25 % | $ 12.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 185.92 | 1.65 % | $ 53.5 B | USA |
 |
The Cooper Companies
COO
|
683 M | $ 53.27 | 0.58 % | $ 10.6 B | USA |
 |
BioLife Solutions
BLFS
|
-16.6 M | $ 36.39 | 2.71 % | $ 1.74 B | USA |
 |
electroCore
ECOR
|
-13.2 M | $ 10.05 | 2.97 % | $ 85.3 K | USA |
 |
Glaukos Corporation
GKOS
|
-200 M | $ 171.68 | 0.34 % | $ 9.82 B | USA |
 |
Haemonetics Corporation
HAE
|
157 M | $ 106.2 | 0.03 % | $ 5.01 B | USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 7.98 | 0.75 % | $ 354 M | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 155.88 | 0.72 % | $ 3.84 B | USA |
 |
InfuSystem Holdings
INFU
|
11.9 M | $ 12.26 | 0.08 % | $ 253 M | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 111.88 | 2.95 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 377.16 | 0.01 % | $ 135 B | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 3.16 | 0.64 % | $ 146 M | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 80.24 | 0.22 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 1.44 | 0.34 % | $ 65.9 M |  Israel |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.4 | 1.42 % | $ 32.8 M | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 86.18 | 0.76 % | $ 5.1 B | USA |
 |
Nephros
NEPH
|
1.15 M | $ 4.29 | 0.45 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 24.73 | 0.94 % | $ 4.15 B | USA |
 |
Pro-Dex
PDEX
|
13 M | $ 66.91 | 0.53 % | $ 216 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 55.2 | 1.83 % | $ 3.72 B | USA |
 |
ResMed
RMD
|
1.89 B | $ 229.44 | 2.92 % | $ 33.4 B | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 22.45 | 1.81 % | $ 1.11 B | USA |
 |
STERIS plc
STE
|
1.1 B | $ 210.28 | 1.36 % | $ 20.6 B | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 129.02 | 0.19 % | $ 5.76 B | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 3.46 | 2.67 % | $ 254 M | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 74.63 | 5.6 % | $ 242 M | USA |
 |
Repligen Corporation
RGEN
|
55.2 M | $ 174.73 | 4.01 % | $ 9.83 M | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 365.0 | 2.76 % | $ 26.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 9.83 | 0.62 % | $ 1.96 B | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.32 | 3.1 % | $ 120 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-37.5 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |